Syneos Health Announces Pricing of Secondary Presenting of Typical Stock – June 03, 2021
MORRISVILLE, N.C., June 03, 2021 (World NEWSWIRE) — Syneos Health and fitness, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only thoroughly integrated biopharmaceutical methods group, these days declared the pricing of the previously declared underwritten secondary supplying by affiliate marketers of Thomas H. Lee Companions, L.P. and Arrival Global Corporation (the “Selling Stockholders”) of an combination of 10,851,676 shares of the Company’s typical inventory (the “Offering”). Syneos Wellbeing is not offering any shares and will not acquire any proceeds from the proposed sale of the shares by the Marketing Stockholders in the Giving. The Giving is envisioned to close on June 7, 2021, issue to customary closing disorders.
In addition, Syneos Overall health entered into an settlement with the Offering Stockholders to repurchase an mixture of 500,000 shares of frequent stock from this sort of Marketing Stockholders in a non-public transaction, concurrently with the closing of the Providing, at the price tag at which the shares of frequent stock are marketed to the public in the Providing, considerably less underwriting reductions and commissions. The closing of the share repurchase is contingent on, and expected to manifest at the same time with, the closing of the Providing, topic to the fulfillment of other customary problems. The closing of the Supplying is not contingent on the closing of the share repurchase.
BofA Securities is acting as the sole underwriter of the Offering.
An automated shelf registration assertion (which include a prospectus) relating to the Featuring was filed with the Securities and Exchange Commission (“SEC”) on November 27, 2018 and turned efficient on filing. Before you invest, you really should read through the registration assertion, prospectus and other paperwork Syneos Overall health has created obtainable with the SEC for information and facts about Syneos Health and the Providing. You could get these files totally free of charge by checking out EDGAR on the SEC web site at www.sec.gov. Alternatively, copies of the prospectus and accompanying prospectus nutritional supplement, when available, may perhaps be acquired from:
BofA Securities, Inc.

NC1-004-03-43

200 North School Street, 3rd ground

Charlotte NC 28255-0001

Attn: Prospectus Section

E mail: [email protected]
This push launch shall not represent an give to offer or the solicitation of an offer to purchase, nor shall there be any sale of these securities in any state or other jurisdiction in which these types of an provide, solicitation or sale would be illegal prior to registration or qualification less than the securities regulations of any these types of state or other jurisdiction.
Ahead-Looking Statements
Except for historic information and facts, all of the statements, expectations, and assumptions contained in this press launch are forward-searching statements as that phrase is outlined in the Personal Securities Litigation Reform Act of 1995. Real benefits may possibly vary materially from individuals explicit or implicit in the ahead-hunting statements. Critical aspects that could lead to actual benefits to vary materially involve, but are not minimal to: reliance on key staff principal investigators and clients typical and international economic, political, and other risks, which include currency and stock market place fluctuations and the unsure economic atmosphere any failure to realize the anticipated benefits of the acquisitions of SHCR Holdings Company, or Synteract, and Illingworth Investigate Team dangers similar to the COVID-19 pandemic the Company’s capacity to sufficiently price tag its contracts and not overrun cost estimates any adverse consequences from the Company’s consumer or therapeutic spot concentration the Company’s ability to sustain or crank out new small business awards the Company’s potential to raise its marketplace share, develop its small business, and execute its advancement methods the Company’s backlog not being indicative of long term revenues and its capability to know the expected upcoming earnings reflected in its backlog fluctuations in the Company’s functioning success and effective earnings tax charge risks relevant to the Company’s information and facts systems and cybersecurity modifications and fees of compliance with rules associated to details privateness challenges similar to the United Kingdom’s withdrawal from the European Union hazards connected to the Company’s transfer pricing guidelines failure to perform products and services in accordance with contractual prerequisites, regulatory demands and ethical considerations pitfalls relating to litigation and authorities investigations risks linked with the Company’s early section clinical amenities insurance policies threat dangers of liability resulting from hurt to sufferers results of investments in the Company’s customers’ company or prescription drugs international currency exchange charge fluctuations risks associated with obtained enterprises, including the skill to combine obtained operations, merchandise, and systems in our enterprise challenges associated to the Company’s earnings tax expenditure and tax reform risks relating to the Company’s intellectual property dangers affiliated with the Company’s acquisition strategy failure to notice the complete price of goodwill and intangible property restructuring possibility likely violations of anti-corruption and anti-bribery guidelines threats similar to the Company’s dependence on third functions downgrades of the Company’s credit rating ratings level of competition in the biopharmaceutical products and services market adjustments in outsourcing traits regulatory hazards traits in the Company’s customers’ organizations the Company’s skill to hold pace with fast technological transform dangers relevant to the Company’s indebtedness fluctuations in the Company’s fiscal outcomes and stock selling price and other possibility factors set forth in the Company’s Yearly Report on Form 10-K for the fiscal calendar year ended December 31, 2020 and other SEC filings, copies of which are available no cost of demand on the SEC web-site at www.sec.gov. The Organization assumes no obligation and does not intend to update these ahead-seeking statements, other than as essential by law.
About Syneos Health and fitness
Syneos Wellbeing® (Nasdaq:SYNH) is the only absolutely integrated biopharmaceutical remedies corporation. The Organization, together with a Agreement Research Corporation (CRO) and Deal Business Group (CCO), is purpose-crafted to accelerate consumer effectiveness to handle fashionable industry realities. We carry together roughly 25,000 medical and business minds with the capacity to assistance buyers in additional than 110 nations around the world. Together we share insights, use the hottest technologies and apply superior enterprise tactics to speed our customers’ supply of critical therapies to sufferers.

